Recently, the results of the prospective, multicenter, single-arm phase II clinical study of carilizumab in combination with apatinib and albumin paclitaxel in advanced lung adenocarcinoma (CAPAP-lung), led by Prof. Wu Lin of Hunan Cancer Hospital, have been published in The Lancet (IF=15.1) and eClinicalMedicine (IF=15.1), which is a subseries of The Lancet. eClinicalMedicine (IF=15.1).1 The results of the study showed that the first-line treatment of advanced lung adenocarcinoma negative for epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations with karelizumab in combination with apatinib (the "double-Ai" combination) and albumin paclitaxel demonstrated a clinically meaningful antitumor effect. Demonstrated clinically meaningful antitumor activity and a manageable safety profile with low hematological toxicity. This study is the first exploration of advanced non-small cell lung cancer (NSCLC) treated with platinum-free chemotherapy in combination with immunologic agents and anti-vascular drugs, and is expected to provide new options for first-line treatment of EGFR/ALK mutation-negative advanced lung adenocarcinoma.

This is the first exploration of platinum-free chemotherapy combined with immunotherapy and anti-vascular agents in the first-line treatment of advanced lung adenocarcinoma. In this study, the use of platinum-free chemotherapy in combination with immunotherapy and anti-vascular drugs (karelizumab in combination with apatinib and albumin paclitaxel) for the first-line treatment of patients with advanced lung adenocarcinoma who were negative for EGFR/ALK mutations showed clinically meaningful anti-tumor activity and a manageable safety profile, which is expected to offer a potentially alternative option for the first-line treatment of patients with advanced lung adenocarcinoma.

https://mp.weixin.qq.com/s/y11BKXxzad2fXC0wnJQqxg